主页 > 医学动态 >
【bio-news】一种与卵巢肿瘤细胞生长有关的RNA剪接
04/09/07 -- An RNA-binding protein that is overproduced in ovarian cancer may present a new target for diagnosis or treatment of ovarian and other cancers, according to researchers at the University of Illinois at Chicago.
Researchers in the UIC College of Pharmacy found that interfering with the production of a splicing factor can inhibit the growth and invasiveness of tumor cells in test-tube experiments.
"In a previous study, we observed that human ovarian tumors overexpressed polypyrimidine tract-binding protein, or PTB, and another splicing factor compared to normal matching ovarian tissues," said William Beck, professor and head of biopharmaceutical sciences.
In the new study, Beck and research assistant professor Xiaolong He show that knocking down PTB expression with small, interfering RNA "substantially impairs ovarian tumor cell growth, colony formation and invasiveness."
The research has been published in the online version of the journal Oncogene; it will appear in an upcoming issue of the journal's print version.
Ovarian cancer is commonly referred to as "the silent killer," as it usually is not discovered until its advanced stages. If diagnosed and treated while the cancer is confined to the ovary, the 5-year survival rate is more than 90 percent, according to the American Cancer Society. Unfortunately, only 19 percent of all cases are found in the early stages.
One woman in 58 will develop ovarian cancer during her lifetime, the American Cancer Society said. In 2006, it was estimated that there were 20,180 new cases of ovarian cancer; 15,310 women were expected to die from the disease.
"Ovarian cancer is the deadliest disease among all gynecological cancers," said He. "Two factors account for the dismal mortality outcomes. One is the absence of reliable early detection markers, and the other is inadequacy of present therapy for advanced disease. To improve patient survival, it is critical to identify new biomarkers for early detection."
Polypyrimidine tract-binding protein is a key regulator of splicing, Beck said. Defects in pre-messenger RNA splicing have been shown to cause a variety of human diseases. Evidence suggests that altered splicing is associated with and possibly involved in tumor progression or metastasis.
"To the best of our knowledge, this is the first time anyone has shown that interference with the production of a splicing factor can inhibit tumor cell growth and tumor invasiveness," Beck said. "Alternatively-spliced genes and splicing factors are likely to play a key role as therapeutic targets and diagnostic markers in the next decade."
Source: University of Illinois at Chicago
http://www.bio.com/newsfeatures/newsfeatures_research.jhtml?cid=28200001 RNA Splicing Factor Implicated in Ovarian Tumor Cell Growth
一种与卵巢肿瘤细胞生长有关的RNA剪接因子
04/09/07 -- An RNA-binding protein that is overproduced in ovarian cancer may present a new target for diagnosis or treatment of ovarian and other cancers, according to researchers at the University of Illinois at Chicago.
2007年4月9日芝加哥伊利诺大学的研究人员报道，卵巢癌中过度分泌的一种RNA结合蛋白可能成为诊断或治疗卵巢癌或其他癌症的新靶标。
Researchers in the UIC College of Pharmacy found that interfering with the production of a splicing factor can inhibit the growth and invasiveness of tumor cells in test-tube experiments.
芝加哥伊利诺大学药学院的研究人员发现在试管实验中抑制剪接因子的合成可阻断肿瘤细胞的生长与侵袭。
"In a previous study, we observed that human ovarian tumors overexpressed polypyrimidine tract-binding protein, or PTB, and another splicing factor compared to normal matching ovarian tissues," said William Beck, professor and head of biopharmaceutical sciences.
生物制药科技主任William Beck教授说：“在以前的研究中，我们发现，与正常卵巢组织相比，人卵巢肿瘤过度表达多嘧啶环结合蛋白（PTB）及另一个剪接因子。”
In the new study, Beck and research assistant professor Xiaolong He show that knocking down PTB expression with small, interfering RNA "substantially impairs ovarian tumor cell growth, colony formation and invasiveness."
在这项新研究中，Beck和他的研究助手何小龙教授指出，用小型干扰RNA敲除PTB的表达的确抑制了肿瘤细胞生长、克隆形成和侵袭。
The research has been published in the online version of the journal Oncogene; it will appear in an upcoming issue of the journal's print version.
这项研究成果已经在《肿瘤基因杂志》网络版发表，将在下期杂志印刷版出版。
Ovarian cancer is commonly referred to as "the silent killer," as it usually is not discovered until its advanced stages. If diagnosed and treated while the cancer is confined to the ovary, the 5-year survival rate is more than 90 percent, according to the American Cancer Society. Unfortunately, only 19 percent of all cases are found in the early stages.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-06 05:11
医学,生命科学网